Stockscreener 앱 받기
8.47
1.17%
-0.10
시간 외 거래:
8.69
0.22
+2.60%
전일 마감가:
$8.57
열려 있는:
$8.46
하루 거래량:
1.15M
Relative Volume:
0.64
시가총액:
$737.04M
수익:
-
순이익/손실:
$-168.09M
주가수익비율:
-3.9032
EPS:
-2.17
순현금흐름:
$-138.01M
1주 성능:
-1.51%
1개월 성능:
-20.32%
6개월 성능:
+35.96%
1년 성능:
+7.08%
1일 변동 폭
$8.355
$8.615
1주일 범위
$8.355
$9.175
52주 변동 폭
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
KURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.47 | 745.74M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura oncology CSO Burrows sells $11k in shares By Investing.com - Investing.com India
Kura Oncology CCO Powl sells $54,266 in stock By Investing.com - Investing.com Australia
Kura Oncology COO Ford sells $15,339 in stock - Investing.com
Kura Oncology SVP sells $60k in shares - Investing.com
Kura Oncology CCO Powl sells $54,266 in stock - Investing.com
Understanding Momentum Shifts in (KURA) - Stock Traders Daily
Sector Gamma AS Takes $3.88 Million Position in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology, Inc. (KURA) Rating Update: 258% Potential Upside Highlights Growth Potential In Biotech Sector - directorstalkinterviews.com
Kura Oncology (NASDAQ:KURA) Cut to "Strong Sell" at Zacks Research - MarketBeat
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology (NASDAQ:KURA) Nasdaq 100 Index Clinical Research Focus - Kalkine Media
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Does Kura Oncology (NASDAQ:KURA) Have A Healthy Balance Sheet? - 富途资讯
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 37.5% in December - MarketBeat
Kura Oncology's finance SVP sells shares worth $38,958 - MSN
Kura Oncology price target lowered to $20 from $25 at Leerink - Yahoo Finance
FY2025 EPS Forecast for Kura Oncology Reduced by Analyst - MarketBeat
Kura Oncology (KURA) Receives a Buy from Leerink Partners - The Globe and Mail
Inflation Data: Will Kura Oncology Inc stock keep outperforming rivalsJuly 2025 PreEarnings & Risk Controlled Swing Alerts - Bộ Nội Vụ
KURA: HC Wainwright & Co. Reiterates 'Buy' Rating and $40 PT | K - GuruFocus
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
Stock Recap: Whats the profit margin of Kura Oncology IncIPO Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA) - The Globe and Mail
Kura Oncology 8-K Filing Analysis - TradingView
Kura Oncology Posts $2.1M Initial KOMZIFTI Sales, Secures $195M Milestone - Nasdaq
Kura Oncology Announces Launch of KOMZIFTI™ (ziftomenib) and Preliminary $2.1 Million Revenue Following FDA Approval for R/R NPM1-mutated AML - Quiver Quantitative
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - The Manila Times
Kura Oncology wins FDA approval for leukemia drug - MSN
Is Kura Oncology Inc. stock affected by interest rate hikesTrade Performance Summary & Fast Gain Stock Tips - Улправда
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors - Yahoo Finance
Can Kura Oncology Inc. stock sustain institutional interestJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
Rate Cut: Will Kura Oncology Inc. stock see insider buyingEarnings Summary Report & Consistent Return Strategy Ideas - Улправда
Aug Intraday: Is Kura Oncology Inc. stock affected by interest rate hikesWeekly Stock Analysis & Verified Swing Trading Watchlist - Улправда
FY2025 EPS Forecast for Kura Oncology Decreased by Analyst - MarketBeat
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" - Finviz
Kura Oncology (STU:KUR) EV-to-FCF : 3.00 (As of Dec. 23, 2025) - GuruFocus
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
7 Stocks That Were on Jim Cramer’s Radar - Insider Monkey
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):